Asset Publisher

null Agathe Leon´s group


Our group works in three different areas of the AIDS research group integrated at IDIBAPS. These areas are line 3 of immunopatogenia and vaccines, line 9 of prevention strategies (PEP and PREP) and line 12 of new models of care.

Main areas of interest in line 3 are pathogenic mechanisms linked to the absence of viral infection after exposure to HIV in Highly Exposed Persistently Seronegative subjects, replication control and immune response to the virus on HIV controllers. In collaboration with other Spanish investigators we have created few years ago the Elite controllers working group of the Spanish AIDS Research Network. Research projects evaluating loss of virologic and immunological control of controllers are ongoing projects.

In the area of prevention strategies our group coordinates in Hospital Clinic the PEP clinic attending yearly 1400 individuals with an HIV risk exposition. We have done several clinical trials evaluating different cART in PEP. We are currently participating in an European joint action called INTEGRATE which has the aim of integrating prevention, testing and link to care strategies across HIV, viral hepatitis, TB and STIs in Europe.

Line 12 of new models chronic HIV stable patients is focus on the development of new strategies for caring chronic patients in a non hospital-based manner, such as through non face to face consultations using telemedicine [ (internet) or mheath (application through mobile devices)] or sharing HIV care with general providers. This group has been running a Virtual Hospital for patients living with stable HIV since 2005. The Virtual Hospital is an internet based home-care system that offers virtual consultations, telepharmacy, a virtual library of information and a virtual community. Nowadays this virtual clinic has become clinical routine and we are currently involved in an Horizon2020 research project (EMERGE, grant agreement no: 643736) to validate a mobile application platform in 4000 stable patients.

Related Assets


Agathe Leon
Eva Gonzalez de la Fuente
Eva Gonzalez Redondo
Carmen Mensa
Marta Sala

Related Assets

Related Assets


  • Early Detection of HIV infection and of Asymptomatic Sexually Transmitted Infections among Men who have Sex with Men 
    Coll P, Videla J, Leon A*, Ornelas A, Garcia F, Fernandez E, Blanco JL, Meulbroek M, Carrillo A, Bravo I, Garcia-Cuyas F, Gonzalez V, Casabona J, Clotet B, Brander C.  Clinical Microbiology and Infection 2017 Aug 23 
  • Monocytes Phenotype and cytokine Production in human immunodeficiency Virus-1 infected Patients receiving a Modified Vaccinia ankara-Based hiV-1 Vaccine: relationship to cD300 Molecules expression 
    Vitallé J, Zenarruzabeitia O, Terrén I, Plana M, Guardo AC, Leal L, Peña J, García F, Borrego F on behalf of the RISVAC-03 Study Group† (León A*).  Frontiers in Immunology 2017; 8: 836. Pp 1-11. 
  • Adenosine deaminase regulates Treg expression in autologous T cell-dendritic cell cocultures from patients infected with HIV-1. 
    Naval-Macabuhay I, Casanova V, Navarro G, Garcia F, León A*, Miralles L, Rovira C, martinez-navio JM, Gallart T, Mallolas J, Gatell JM, Lluis C, Franco R, McCormick PJ, Climent N.  Journal of Leukocyte Biology 2016; 99-2, pp.349-408. ISSN 1938-3673. 
  • Rate and predictors of progression in elite and viremic HIV-1 controllers. Tipus de publicació: Original. 
    A Leon*, I Perez, E Ruiz-Mateos, JM Benito, M Leal, C Lopez-Galindez, N Rallon, J Alcami, J Lopez-Aldeguer, P Viciana, C Rodriguez, E Grau, J Iribarren, JM Gatell, F Garcia On behalf of the EC and Immune pathogenesis working group of the Spanish AIDS Research Network*  AIDS. 2016 May 15; 30(8):1209-20. 
  • Spanish AIDS Research Network HIV Controllers Cohort (ECRIS). Analysis of Non-AIDS-Defining Events in HIV Controllers. Tipus de publicació: Original. 
    Dominguez-Molina B, Leon A*, Rodriguez C, Benito JM, Lopez-Galindez C, Garcia F, Del Romero J, Gutierrez F, Viciana P, Alcami J, Leal M, Ruiz-Mateos E;  Clin Infect Dis. 2016 May 15; 62(10):1304-9. 
  • Detection of HIV-1-specific T-cell immune responses in highly HIV-exposed uninfected individuals by in-vitro dendritic cell co-culture. 
    Guardo AC, Ruiz-Riol M, Fernández E, Maleno MJ, Bargalló ME, León A*, Climent N, García F, Gatell JM, Brander C, Plana M.  AIDS 2015 Jul 17; 29(11): 1309-18 
  • Association of microbial translocation biomarkers with clinical outcome in controllers HIV-infected patients. 
    León A*, Leal L, Torres B, Lucero C, Inciarte A, Arnedo M, Plana M, Vila J, Gatell JM, García F.  AIDS 2015 Mar 27; 29(6):675-81. 
  • Safety and immunogenicity of a MVA-based HIV-1 vaccine (MVA-B) in HIV-1-infected patients alone or in combination with a drug to reactivate latent HIV-1. 
    Mothe B, Climent N, Plana M, Rosàs M, Jiménez JL, Muñoz-Fernández MA, Puertas MA, Carrillo J, Gonzalez N, León A*, Pich J, Arnaiz JA, Gatell JM, Clotet B, Blanco J, Alcami J, Martinez-Picado J, Alvarez-Fernandez C, Sanchez-Palomino S, Guardo A, Peña J, Benito J, Rallón N, Gomez C, Perdiguero B, Garcia-Arraiza, J, Mariano E, López J, Brander C, Garcia F.  J Antimicrob Chemother 2015 Jun; 70(6):1833-42. 
  • Alternative effector-function profiling identifies broad HIV-specific T-cell responses in highly HIV-exposed individuals who remain uninfected. 
    Ruiz-Riol M, Llano A, Ibarrondo J, Zamarreño J, Yusim K, Bach V, Mothe B, Perez-Alvarez S, Fernandez MA, Requena G, Meulbroek M, Pujol F, Leon A*, Cobarsi P, Korber BT, Clotet B, Ganoza C, Sanchez J, Coll J, Brander C.  J Infect Dis 2014 Sep 23. 
  • Feasibility and Effectiveness of Indicator Condition-Guided Testing for HIV: Results from HIDES I (HIV Indicator Diseases across Europe Study. 
    Sullivan A, Raben D, Reekie J, Rayment M, Mocroft A, Esser S, Leon A*, Begovac J, Brinkman K, Zangerle R, Grzeszczuk A, Vassilenko A, Hadziosmanovic V, Krasnov M, Sönnerborg A, Clumeck N, Gatell J, Gazzard B, Monforte A, Rockstroh J, Lundgren J.  PLoS One 2013; 8(1):e52845. 

Related Assets